Next Article in Journal
Utilization of Crab Waste for Cost-Effective Bioproduction of Prodigiosin
Previous Article in Journal
Induction of Natural Defenses in Tomato Seedlings by Using Alginate and Oligoalginates Derivatives Extracted from Moroccan Brown Algae
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 18
Issue 10
10.3390/md18100522
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antibacterial Activity of Chromomycins from a Marine-Derived Streptomyces microflavus

by
Eunji Cho
1,
Oh-Seok Kwon
2,
Beomkoo Chung
1,
Jayho Lee
1,
Jeongyoon Sun
1,
Jongheon Shin
2,* and
Ki-Bong Oh
1,*
1
Department of Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea
2
Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Korea
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2020, 18(10), 522; https://doi.org/10.3390/md18100522
Submission received: 23 September 2020 / Revised: 14 October 2020 / Accepted: 20 October 2020 / Published: 21 October 2020
Browse Figures
Review Reports Versions Notes

Abstract

:
A marine-derived actinomycete (Streptomyces sp. MBTI36) exhibiting antibacterial activities was investigated in the present study. The strain was identified using genetic techniques. The 16S rDNA sequence of the isolate indicated that it was most closely related to Streptomyces microflavus. Furthermore, a new chromomycin A9 (1), along with chromomycin Ap (2), chromomycin A2 (3), and chromomycin A3 (4), were isolated from the ethyl acetate extract. Their structures were determined using extensive spectroscopic methods including 1D and 2D NMR, and HRMS, as well as comparisons with previously reported data. Compounds 1–4 showed potent antibacterial activities against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). During a passage experiment, minimum inhibitory concentration (MIC) values for compounds 1–4 showed no more than a 4-fold increase from the starting MIC value, indicating that no resistance was detected over the 21 passages.

1. Introduction

Antibiotic resistance is an increasing threat to global health [1]. The development of new antimicrobial drugs is a priority to combat the increasing spread of antibiotic-resistant bacteria [2,3]. Since the discovery of antibiotics, the majority of new antibiotics have been isolated from actinomycetes, especially Streptomyces spp.; however, the number of newly discovered antibiotics continues to decrease [4]. To solve this problem, many scientists have focused on marine microorganisms. The deep sea environment provides unique growth conditions for microorganisms, such as minimal light, high pressure, salinity, extreme temperature, and lack of oxygen [5,6]. The different environment might confer unusual features on marine actinomycetes; thus, in comparison with their terrestrial counterparts, new bioactive secondary metabolites could be produced [7]. Therefore, actinomycetes from marine habitats can be a rich source of structurally unique natural compounds with diverse biological activities, including antibacterial and anticancer activities [8].
Chromomycins are members of the aureolic acid family, which were first isolated from Streptomyces griseus No. 7 (ATCC No. 13273) [9]. Members of this family, which include mithramycin, olivomycin, durhamycin, and chromomycin, are glycosylated aromatic polyketides with potent antitumor and antibacterial activities [10]. These polyketides have a tricyclic aglycone core with two aliphatic side chains at C-3 and C-7 and two sugar chains at C-2 and C-6. The compounds are distinguished by the type of sugar; chromomycins have a disaccharide chain consisting of two d-olioses at C-2 and a trisaccharide chain consisting of two D-olivoses and L-chromose. Chromomycins possess a broad range of biological activities such as antimicrobial [10,11], anticancer [12,13,14], and antiviral [15] activities, and are found in terrestrial and marine bacteria of the genus Streptomyces. Similar to other aureolic acid family members, chromomycins interact with the DNA helix minor groove in regions with high GC content and in a non-intercalative way with Mg2+ cations, causing DNA damage in treated cells [16,17,18].
When searching for bioactive secondary metabolites from marine-derived actinomycetes, we characterized a strain, MBTI36, collected from marine sediment from Jeju Island, Korea, and identified it as Streptomyces microflavus based on 16S rDNA analysis. An organic extract of a liquid culture of this strain exhibited potent antibacterial activity, with a minimum inhibitory concentration (MIC) value of 0.5 μg/mL, against Staphylococcus aureus, a Gram-positive pathogenic bacterium. Antibacterial activity-guided separation of the extract using diverse chromatographic methods led to the isolation of a new chromomycin derivative A9 (1), with the known chromomycins Ap (2), A2 (3), and A3 (4). Herein, the structure of a new chromomycin A9 (1) and the antibacterial activity spectrum of compounds 1–4 against several representative pathogenic microorganisms including methicillin-resistant Staphylococcus aureus (MRSA) are reported.

2. Results

2.1. Taxonomy and Phylogenetic Analysis of MBTI36

The 16S rDNA of strain MBTI36 was amplified using polymerase chain reaction (PCR) and sequenced (1389 bp). After a basic logic alignment search tool (BLAST) sequence comparison, strain MBTI36 showed 99.9% identity to Streptomyces microflavus NBRC13062 (type strain, GenBank accession number: NR1123524), S. microflavus strain DR009 (GenBank accession number: JQ422181), strain PM122 (GenBank accession number: JQ422127), and strain PM100 (GenBank accession number: JQ422182). Thus, this strain was designated as Streptomyces microflavus strain MBTI36 (GenBank accession number: MK396664). The phylogenetic tree generated using the neighbor-joining and maximum likelihood method based on the 16S rDNA sequence revealed the evolutionary relationships of MBTI36 with a group of known Streptomyces type strains (Figure 1).

2.2. Isolation and Structural Elucidation of Compounds 1–4

Strain MBTI36 was cultured in GTYB (10 g of glucose, 2 g of tryptone, 1 g of yeast extract, and 1 g of beef extract in 1 L of artificial seawater) broth and cultivated for 14 days without shaking. The culture filtrate was lyophilized and extracted with methanol. After evaporation of the solvent, the crude extract was separated using solvent-partitioning followed by semi-preparative high-performance liquid chromatography (HPLC) to yield four compounds. Based on combined spectroscopic analyses, including 1H, 13C nuclear magnetic resonance (NMR), two-dimensional (2D) NMR spectral analyses (COSY, HMQC, and HMBC), and UV data, compounds 2–4 were identified as chromomycin Ap (2) [19], chromomycin A2 (3) [20,21], and chromomycin A3 (4) [9,22] (Figure 2). The spectroscopic data for these compounds were in good agreement with previous reports.
The molecular formula of compound 1 was determined to be C58H84O26 based on high-resolution fast atom bombardment mass spectrometry (HR-FAB-MS) analysis ([M + Na]+ m/z 1219.5143, calcd for C58H84O26Na, 1219.5149) having 17 degrees of unsaturation. The 13C NMR data of this compound showed signals of two ketone carbons at δC 211.3 and 202.3, which were supported by a strong absorption band at 1722 cm−1 in the IR data. Similarly, two additional carbonyl carbons at δC 174.6 and 171.7, in conjunction with the absorption band at 1731 cm−1 in the IR data, were assigned as ester carbons. The 13C NMR data showed 10 deshielded carbons in the region of δC 159.9–101.0 with the corresponding proton signals at δH 6.76 and 6.64 in the 1H NMR data (Table 1), indicative of a naphthalene-type aromatic moiety. In addition, more than 20 oxygen-bearing methines and methylenes were observed, indicating the presence of several sugar units. For these, the five anomeric carbons at δC 100.5–95.4 and the corresponding protons at δH 5.21–4.60 in the 13C and 1H NMR data, respectively, defined the presence of five sugars. Because these preliminary interpretations accounted for 16 degrees of unsaturation (4 for carbonyls, 7 for naphthalene, and 5 for sugars), compound 1 must possess an additional cycle for the 17 degrees of unsaturation inherent from the mass data. All the structural features coincide well with congener chromomycins Ap (2), A2 (3), and A3 (4), indicating that 1 is a new member of this class.
Based on this information, the structure of 1 was determined by comparing the 13C and 1H NMR data with other chromomycins as well as combined 2D NMR analyses (Figure 3, Figures S1–S6). First, the aromatic carbons and protons had almost the same chemical shifts as congeners assigned the tri-oxygenated methylnaphthalene moiety (C-4-C-10, C-4a, C-8a, C-9a, and C-10a) in 1. This interpretation was confirmed based on 1H-1H COSY, HSQC, and HMBC data including the long-range correlations of key protons (H-5, H-10, and 7-H3) with neighboring carbons. The expansion of this moiety was also determined based on combined COSY (H-2-H-3-H2-4) and HMBC correlations (H-2/C-1, H2-4/C-4a, and H-5/C-4) to construct a dihydroxy-3,4-dihydroanthracen-1-one moiety, the common aglycone of the chromomycin class. Then, an additional COSY correlation of H-3 placed a methoxy-bearing methine (C-1′) at this position. A COSY-based 2,3-dihydroxypropyl group (C-3′-C-5′) was connected at this methine via a ketone (C-2′) based on HMBC correlations (H-1′/C-2′ and H-3′/C-2′), establishing a five carbon side chain that was previously reported for the chromomycin family.
The 13C and 1H NMR and 2D NMR data for the sugar portion of 1 were also similar to 4, indicating the same sugar identities and connectivity (Table 1). Consequently, the five sugar units were identified as two D-olioses, two D-olivoses, and one L-chromose, based on the comparison of NMR data with 4 using COSY correlations among the sugar protons. Subsequently, the linkage between the sugar moieties and their connection at the aglycone were secured by 3-bond HMBC correlations of anomeric carbons with protons (Figure 3). However, an ethyl group was identified based on the COSY and HSQC data (δC 27.8, δH 2.46; δC 9.7, δH 1.19). The attachment of this group at C-A4 of D-oliose (sugar A) via a ketone (δC 174.6) was also found based on a series of HMBC correlations, replacing the 4-O-acetyl substituent of 4 with the 4-O-propioyl group in 1. Thus, the structure of compound 1 (chromomycin A9) was determined to be a new chromomycin possessing a 4-O-propioyl-D-oliose moiety.

2.3. Antimicrobial Activity of Compounds 1–4

The antimicrobial activities of compounds 1–4 were evaluated against phylogenetically diverse pathogenic bacterial and fungal strains. These compounds displayed significant antibacterial activity against the Gram-positive strains tested (Staphylococcus aureus ATCC25923, Enterococcus faecium ATCC19434, and E. faecalis ATCC19433), with MIC values of 0.03–0.5 μg/mL (Table 2). However, the compounds did not show inhibitory activity against Gram-negative bacteria such as Klebsiella pneumoniae ATCC10031 and Escherichia coli ATCC25922 (MIC > 128 μg/mL), except for Salmonella enterica ATCC14028 (MIC = 0.5–1 μg/mL) when using ampicillin and tetracycline as positive control compounds. The antifungal activities of compounds 1–4 were also evaluated against pathogenic fungal strains, including Candida albicans ATCC10231, Aspergillus fumigatus HIC6094, Trichophyton rubrum NBRC9185, and Trichophyton mentagrophytes IFM40996, using amphotericin B as a positive control compound. However, these compounds did not exhibit inhibitory activity against the tested fungi. Based on the data, compounds 1–4 were further evaluated against drug-resistant S. aureus strains. These compounds exhibited potent antibacterial activities against all methicillin-sensitive S. aureus (MSSA) and MRSA strains (Table 3). Notably, compounds 1–4 showed significant broad-spectrum antibiotic effects on MRSA strains with MIC values of 0.06–0.25 μg/mL, which are more potent than the values of major classes of antibiotics that include daptomycin (MIC > 32 μg/mL), vancomycin (MIC = 0.5–2 μg/mL), platensimycin (MIC = 4–8 μg/mL), linezolid (MIC = 1–2 μg/mL), and ciprofloxacin (MIC = 0.13– > 32 μg/mL).

2.4. Multi-Step Resistance Development

The potential for resistance development to compounds 1–4 in a MRSA strain was also investigated. Representative resistance development profiles for ciprofloxacin (a comparator antibiotic) and compounds 1–4 against S. aureus ATCC43300 are presented in Figure 4. In the present study, resistance was defined as a >4-fold increase in the initial MIC [23,24]. A steady increase in MIC was observed for ciprofloxacin during the passage experiment in S. aureus ATCC43300, with a final MIC of 32 μg/mL, a 128-fold change compared with the initial MIC value (MIC = 0.25 μg/mL). Conversely, for compounds 1–4, a 2-fold increase in the MIC (from 0.13 to 0.25 μg/mL, from 0.13 to 0.25 μg/mL, from 0.06 to 0.13 μg/mL, and from 0.13 to 0.25 μg/mL, respectively) was observed for S. aureus ATCC43300 after 21 passages. During the passage experiment, MIC values for compounds 1–4 showed no more than a 4-fold increase from the starting MIC value, indicating that resistance did not develop during the 21 passages.

3. Discussion

Chromomycins, members of the aureolic acid family, are tricyclic glycosylated polyketides with a broad range of bioactivity spectrums including antimicrobial and anticancer activity that are produced by terrestrial and marine Streptomycete species. In the present study, a chemical investigation of a liquid culture extract of the marine-derived actinomycete S. microflavus strain MBTI36 led to the isolation of four chromomycin derivatives (1–4). The structures of compounds 2–4 were elucidated based on spectroscopic data and comparisons with previously reported data [9,19,20,21,22], and were identified as chromomycin Ap (2), chromomycin A2 (3), and chromomycin A3 (4). The 13C and 1H NMR spectroscopic data of compound 1 were similar to congener compounds 2–4, indicating 1 as a new member of this class. Similar to compound 4, the linkage among the sugar moieties and their attachments to the aglycone were the same; however, the COSY and HSQC data showed an ethyl group in compound 1. The attachment of this group at C-A4 of D-oliose (sugar A) via a ketone was also found based on a series of HMBC correlations, replacing the 4-O-acetyl substituent of 4 with the 4-O-propioyl group in 1. Thus, the structure of compound 1 was determined to be a new chromomycin A9 possessing a 4-O-propioyl-D-oliose moiety.
Chromomycins, especially chromomycin A3 (4), were previously isolated from Streptomycete species including S. griseus and S. cavourensis [9,10] and showed antibacterial activity against Gram-positive bacteria such as Bacillus subtilis, S. aureus, and Enterococcus hirae [11]. In the present study, the isolated compounds 1–4 displayed significant antibacterial activity against Gram-positive pathogenic strains such as S. aureus, E. faecium, and E. faecalis, with MIC values of 0.03–0.5 μg/mL. These compounds also exhibited potent inhibitory activities against MRSA strains, with MIC values of 0.06–0.25 μg/mL, which are more potent than values of major classes of antibiotics that include vancomycin and linezolid. The potential for development of resistance to compounds 1–4 in the MRSA strain S. aureus ATCC43300 was also investigated. As shown in Table 3, ciprofloxacin showed potent antibacterial activities against MRSA strains S. aureus ATCC43300 and ATCC700787. However, based on multi-step (21-passage) resistance selection studies in the presence of sub-inhibitory concentrations of ciprofloxacin (a comparator antibiotic), a steady increase in MIC for ciprofloxacin against S. aureus ATCC43300 during the passage experiment was observed (Figure 4). Reportedly, topoisomerase IV is the primary target of fluoroquinolones in S. aureus, which may be due to the greater sensitivity of topoisomerase IV, relative to DNA gyrase, to these agents [25]. Furthermore, resistance from an altered DNA gyrase requires resistant topoisomerase IV for expression [25,26]. By contrast, during the passage experiment, MIC values for compounds 1–4 showed no more than a 4-fold increase from the starting MIC value, indicating resistance did not develop during the 21 passages.
Members of the aureolic acid family of antibiotics including chromomycins were isolated in the present study based on their antimicrobial activity against Gram-positive bacteria. However, the compounds were not active against Gram-negative bacteria due to permeability problems; thus, the main pharmacological interest resides in their antitumor activity [10]. In several studies, the antitumor activities and mode of action of aureolic acid family antibiotics was shown to be partly due to a non-intercalating interaction with GC regions in the minor groove of the DNA double helix by forming dimeric complexes with Mg2+ [16,17,18]. A suggested mechanism of action involves the binding of chromomycin A3 to DNA as a Mg2+ dimer, which cross-links the two strands, thus blocking the processes of replication and mainly, transcription of DNA, resulting in cytotoxic activity. Therefore, modifications of the side chain can potentially be exploited for modulation of the biological activity of chromomycin compounds. Chromomycins derived from marine actinomycetes should be further investigated.

4. Materials and Methods

4.1. General Experimental Equipments

Optical rotations were measured using a JASCO P-1020 polarimeter (Jasco, Tokyo, Japan) with a 1 cm cell. UV spectra were acquired using a Hitachi U-3010 spectrophotometer (Hitachi, Tokyo, Japan). IR spectra were recorded on a JASCO 4200 FT-IR spectrometer (JASCO, Easton, MD, USA) using a ZnSe cell. NMR spectra were recorded in CDCl3 with the solvent peaks (δH 7.26/δc 77.2) as internal standards on a JEOL JNM 400 MHz NMR spectrometer (JOEL, Peabody, MA, USA). HR-FAB-MS data were obtained at the National Center for Inter-University Research Facilities (NCIRF), Seoul National University, and acquired using a JEOL JMS 700 mass spectrometer (Jeol, Tokyo, Japan) with 6 keV-energy, emission current 5.0 mA, xenon as inert gas, and meta-nitrobenzyl alcohol as the matrix. HPLC separations were performed on a SpectraSYSTEM p2000 equipped with a refractive index detector (SpectraSYSTEM RI-150; Thermo Scientific, Waltham, MA, USA) and a UV-Vis detector (Gilson UV-Vis-151, Gilson, Middleton, WI, USA). All solvents used were of spectroscopic grade or were distilled prior to use.

4.2. Taxonomic Identification of the Chromomycin Producing Microorganism

Marine sediment samples were collected from the shoreline of Jeju Island, Korea. The air-dried sediment (1 g) was mixed with 10 mL of sterilized artificial seawater and shaken at 150 rpm for 30 min at 25 °C. The suspension was serially diluted with sterilized artificial seawater and 0.1 mL volumes of three appropriate dilutions, based on turbidity, were spread onto actinomycete isolation agar plates supplemented with cycloheximide (100 μg/mL) and artificial seawater. Plates were incubated at 28 °C for 2 to 3 weeks. To obtain single strains, colonies were transferred several times on fresh agar plates by streaking.
The isolated bacterial strain MBTI36 was identified using standard molecular biological protocols including DNA amplification and sequencing of the 16S rDNA region. Briefly, genomic DNA was prepared from MBTI36 mycelium using an i-Genomic BYF DNA Extraction Mini Kit (Intron Biotechnology, Seoul, Korea) according to the manufacturer’s protocol. PCR amplification using the primers 27F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1429R (5′- GGTTACCTTGTTACGACTT-3′) was performed under the following conditions: pre-denaturation (95 °C, 5 min), 30 cycles of denaturation (95 °C, 15 s), annealing (50 °C, 30 s), extension (72 °C, 1 min 30 s), and final extension (72 °C, 5 min). The nucleotide sequence was deposited in GenBank under accession number MK396664 and aligned according to nucleotide BLAST (Basic Local Alignment Search Tool, version 2.10) of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) database. The phylogenetic tree was simulated using a neighbor-joining method [27] and evolutionary distances were analysed with the Kimura two-parameter model using MEGA-X software (Molecular Evolutionary Genetics Analysis, version 10, https://megasoftware.net) [28]. The bootstrap was replicated a thousand times.

4.3. Cultivation

MBTI36 was sporulated on GTYB agar plates at 28 °C for 5 days. Mature spores were inoculated in 25 mL GTYB broth at 28 °C for 24 h on a rotatory shaker. Each seed culture was transferred directly to 100 mL of fresh GTYB broth (each flask containing 125 mL of culture broth, 160 flasks used) and incubated at 28 °C for 14 days without shaking.

4.4. Extraction and Isolation

Culture broths were collected from 160 flasks (total 20 L) and filtered through filter paper. Culture filtrate was then lyophilized and extracted three times with 5 L of methanol. After removing the solvent under vacuum, the crude extract was redissolved in water and partitioned with n-hexane (0.4 g) and ethyl acetate (1.83 g). Based on the results of the antibacterial activity assay, the latter fraction was separated using semi-preparative reverse-phase HPLC (Agilent C18 column, 10 × 250 mm; 2.0 mL/min; water-acetonitrile, 50:50) eluting compounds 4 (tR = 15.8 min), 2 (tR = 22.6 min), 1 (tR = 23.4 min), and 3 (tR = 34.5 min) in that order. Further purification for compounds 1 and 2 was accomplished using analytical HPLC (Agilent C18 column, 4.6 × 250 mm; 0.7 mL/min; water-acetonitrile, 55:45). The metabolites were isolated in the following amounts: 6.0, 8.7, 14.1, and 130.0 mg of 1–4, respectively.
Chromomycin A9 (1): pale yellow, amorphous solid; [α] D 25 –18.3 (c 0.25, MeOH); UV (MeOH) λmax (log ε) 205 (3.78), 223 (2.14), 282 (1.93), 317 (1.22), 329 (1.19), 430 (1.34) nm; IR (ZnSe) νmax 3408, 2933, 1731, 1722, 1252, 1167, 1068 cm−1; 13C and 1H NMR data, see Table 1; HR-FAB-MS m/z 1219.5143 [M + Na]+ (calcd for C58H84O26Na, 1219.5149).

4.5. Antibacterial Activity Assays

The antibacterial activity assays were performed according to the Clinical and Laboratory Standards Institute (CLSI) guide methods [29]. Gram-positive bacteria (S. aureus ATCC25923, E. faecium ATCC19434, and E. faecalis ATCC19433) and Gram-negative bacteria (S. enterica ATCC14028, K. pneumoniae ATCC10031, and E. coli ATCC25922) were used for each quality control strain. The following drug-resistant strains were obtained from the stock Culture Collection of Antimicrobial Resistant Microorganisms (CCARM; Seoul Women’s University) and American Type Culture Collection (ATCC) and used for antibacterial activity assays: MSSA strains were CCARM0027, CCARM0204, CCARM0205, and CCARM3640; MRSA strains were CCARM3089, CCARM3090, CCARM3634, CCARM3635, ATCC43300, ATCC700787, and ATCC700788. Cells were cultured overnight in Mueller–Hinton broth (MHB; BD Difco, Sparks, MD, USA) at 37 °C, collected by centrifugation, and washed twice with sterile distilled water. Each test compound was dissolved in dimethyl sulfoxide (DMSO) and diluted with MHB to prepare serial 2-fold dilutions ranging from 0.008 to 128 μg/mL. The final DMSO concentration was maintained at 1% by adding DMSO to the medium according to CLSI guidelines. In each well of a 96-well plate, 90 μL of MHB containing the test compound was mixed with 10 μL of broth containing approximately 5 × 106 colony-forming units (cfu)/mL of test bacterium (final concentration: 5 × 105 cfu/mL) adjusted to match the turbidity of a 0.5 MacFarland standard at 625 nm wavelength. The plates were incubated for 24 h at 37 °C. The MIC was defined as the lowest concentration of test compound that prevented cell growth. Ampicillin (Duchefa, Haarlem, The Netherlands), tetracycline, daptomycin, vancomycin, platensimycin, linezolid, and ciprofloxacin (Sigma-Aldrich, St. Louis, MO, USA) were used as reference compounds.

4.6. Antifungal Activity Assays

The antifungal activity assays were performed in accordance with the guidelines in CLSI document M38 [30]. C. albicans ATCC10231 was cultured on potato dextrose agar (PDA) plates. After incubation for 24 h at 28 °C, yeast cells were harvested by centrifugation and washed twice with sterile distilled water. Filamentous fungi (A. fumigatus HIC6094, T. rubrum NBRC9185, and T. mentagrophytes IFM40996) were cultured on PDA plates at 28 °C for 5 days. Spores were harvested and washed twice with sterile distilled water. Stock solutions of the compound were prepared in DMSO. Each stock solution was diluted in Roswell Park Memorial Institute (RPMI) 1640 broth (Sigma-Aldrich) at a concentration ranging from 0.008 to 128 μg/mL. The final DMSO concentration was maintained at 1% by adding DMSO to the broth. In each well of a 96-well plate, 90 μL of RPMI 1640 containing the test compound was mixed with 10 μL of broth containing approximately 5 × 105 spores/mL of test fungus (final concentration: 5 × 104 spores /mL) adjusted to match the turbidity of a 0.5 McFarland standard. The plates were incubated for 24 h (for C. albicans), 48 h (for A. fumigatus), or 96 h (for T. rubrum and T. mentagrophytes) at 35 °C. The MIC value was determined as the lowest concentration of test compound that fully inhibited cell growth. A culture with DMSO (1%) was used as a solvent control, and a culture supplemented with amphotericin B (Sigma-Aldrich) was used as a positive control.

4.7. Multi-Step Resistance Development Assays

Multi-step resistance development experiments were performed based on methods previously described [31] with minor modifications. The initial inoculum (106 cfu/mL) of S. aureus ATCC43300, a MRSA strain, was prepared in MHB at 35 °C, and adjusted to 0.5 MacFarland standard. A dilution series of 12 concentrations was prepared for ciprofloxacin and compounds 1–4 in fresh MHB based on the previous MIC at 2 × the required final concentration. Next, 50 μL of bacterial inoculum was added to 50 μL of each compound dilution series in a 96-well plate (final concentration: 5 × 105 cfu/mL) and a control plate (no antimicrobial). The plates were incubated at 35 °C for 24 h and the MIC was determined. The cultures were passaged daily for 21 days using 0.5-mL inocula (5 × 105 cfu/mL) from the 96-well plate corresponding to 0.5× the MIC determined from the previous passage to inoculate a fresh series of compound dilutions and control plates.

Supplementary Materials

The following are available online at https://www.mdpi.com/1660-3397/18/10/522/s1, Figure S1: The 1H NMR (400 MHz, chloroform-d) spectrum of 1, Figure S2: The 13C NMR (100 MHz, chloroform-d) spectrum of 1, Figure S3: The COSY (400 MHz, CDCl3) spectrum of 1, Figure S4: The TOCSY (400 MHz, CDCl3) spectrum of 1, Figure S5: The eHSQC (400 MHz, chloroform-d) spectrum of 1, Figure S6: The HMBC (400 MHz, chloroform-d) spectrum of 1.

Author Contributions

E.C. and O.-S.K. carried out isolation and structural elucidation; E.C., B.C., J.L. and J.S. (Jeongyoon Sun) performed the antibacterial and antifungal activity assays; E.C. performed multi-step resistance development assays; J.S. (Jongheon Shin) and K.-B.O. evaluated all data, supervised the research work and prepared the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation (NRF-2018R1D1A1B07043375) of Korea funded by the Ministry of Education, Science and Technology.

Acknowledgments

We are grateful to the National Center for Inter-University Research Facilities, Seoul National University, for providing the mass and NMR data.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kupferschmidt, K. Resistance fighters. Science 2016, 352, 758–761. [Google Scholar] [CrossRef] [Green Version]
  2. Holmes, A.H.; Moore, L.S.; Sundsfjord, A.; Steinbakk, M.; Regmi, S.; Karkey, A.; Guerin, P.J.; Piddock, L.J. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016, 387, 176–187. [Google Scholar] [CrossRef]
  3. Hutchings, M.I.; Truman, A.W.; Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019, 51, 72–80. [Google Scholar] [CrossRef] [PubMed]
  4. Bérdy, J. Thoughts and facts about antibiotics: Where we are now and where we are heading. J. Antibiot. (Tokyo) 2012, 65, 385–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Subramani, R.; Aalbersberg, W. Marine actinomycetes: An ongoing source of novel bioactive metabolites. Microbiol. Res. 2012, 167, 571–580. [Google Scholar] [CrossRef] [PubMed]
  6. Bull, A.T.; Ward, A.C.; Goodfellow, M. Search and discovery strategies for biotechnology: The paradigm shift. Microbiol. Mol. Biol. Rev. 2000, 64, 573–606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Ramesh, S.; Mathivanan, N. Screening of marine actinomycetes isolated from the Bay of Bengal, India for antimicrobial activity and industrial enzymes. World J. Microbiol. Biotechnol. 2009, 25, 2103–2111. [Google Scholar] [CrossRef]
  8. Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2019, 36, 122–173. [Google Scholar] [CrossRef] [Green Version]
  9. Sato, K.; Okamura, N.; Utagawa, K.; Ito, Y.; Watanabe, M. Studies on the antitumor activity of chromomycin A3. Sci. Rep. Res. Inst. Tohoku. Univ. Med. 1960, 9, 224–232. [Google Scholar]
  10. Lombó, F.; Menéndez, N.; Salas, J.A.; Méndez, C. The aureolic acid family of antitumor compounds: Structure, mode of action, biosynthesis, and novel derivatives. Appl. Microbiol. Biotechnol. 2006, 73, 1–14. [Google Scholar] [CrossRef]
  11. Ogawa, H.; Yamashita, Y.; Katahira, R.; Chiba, S.; Iwasaki, T.; Ashizawa, T.; Nakano, H. UCH9, a new antitumor antibiotic produced by Streptomyces: I. Producing organism, fermentation, isolation and biological activities. J. Antibiot. 1998, 51, 261–266. [Google Scholar] [CrossRef] [Green Version]
  12. Pinto, F.C.L.; Silveira, E.R.; Vasconcelos, A.L.C.; Florêncio, K.G.D.; Oliveira, F.A.S.; Sahm, B.B.; Costa-Lotufo, L.V.; Bauermeister, A.; Lopes, N.P.; Wilke, D.V.; et al. Dextrorotatory chromomycins from the marine Streptomyces sp. associated to Palythoa caribaeorum. J. Braz. Chem. Soc. 2020, 31, 143–152. [Google Scholar] [CrossRef]
  13. Mir, M.A.; Majee, S.; Das, S.; Dasgupta, D. Association of chromatin with anticancer antibiotics, mithramycin and chromomycin A3. Bioorg. Med. Chem. 2003, 11, 2791–2801. [Google Scholar] [CrossRef]
  14. Hu, Y.; Espindola, A.P.D.M.; Stewart, N.A.; Wei, S.; Posner, B.A.; MacMillan, J.B. Chromomycin SA analogs from a marine-derived Streptomyces sp. Bioorg. Med. Chem. 2011, 19, 5183–5189. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Bianchi, N.; Rutigliano, C.; Passadore, M.; Tomassetti, M.; Pippo, L.; Mischiati, C.; Feriotto, G.; Gambari, R. Targeting of the HIV-1 long terminal repeat with chromomycin potentiates the inhibitory effects of a triplex-forming oligonucleotide on Sp1-DNA interactions and in vitro transcription. Biochem. J. 1997, 326, 919–927. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Barceló, F.; Ortiz-Lombardía, M.; Martorell, M.; Oliver, M.; Méndez, C.; Salas, J.A.; Portugal, J. DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 2010, 49, 10543–10552. [Google Scholar] [CrossRef] [PubMed]
  17. Zihlif, M.; Catchpoole, D.R.; Stewart, B.W.; Wakelin, L.P. Effects of DNA minor groove binding agents on global gene expression. Cancer Genom. Proteom. 2010, 7, 323–330. [Google Scholar]
  18. Murase, H.; Noguchi, T.; Sasaki, S. Evaluation of simultaneous binding of chromomycin A3 to the multiple sites of DNA by the new restriction enzyme assay. Bioorg. Med. Chem. Lett. 2018, 28, 1832–1835. [Google Scholar] [CrossRef] [PubMed]
  19. Norio, S.; Eiji, H.; Takashi, S.; Mitsuko, A.; Kimiaki, M. Chromomycin Ap. Japan Patent JP 52102202, 23 February 1976. [Google Scholar]
  20. Yoshimura, Y.; Koenuma, M.; Matsumoto, K.; Tori, K.; Terui, Y. NMR studies of chromomycins, olivomycins, and their derivatives. J. Antibiot. 1988, 41, 53–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Miyamoto, M.; Kawamatsu, Y.; Kawashima, K.; Shinohara, M.; Tanaka, K.; Tatsuoka, S.; Nakanishi, K. Chromomycin A2, A3 and A4. Tetrahedron 1967, 23, 421–437. [Google Scholar] [CrossRef]
  22. Toume, K.; Tsukahara, K.; Ito, H.; Ariai, M.A.; Ishibashi, M. Chromomycins A2 and A3 from marine actinomycetes with TRAIL resistance-overcoming and Wnt signal inhibitory activities. Mar. Drugs 2014, 12, 3466–3476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Clark, C.; Kosowska-Shick, K.; McGhee, P.; Dewasse, B.; Beachel, L.; Appelbaum, P.C. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 2009, 53, 3118–3121. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Kosowska-Shick, K.; Clark, C.; Pankuch, G.A.; McGhee, P.; Dewasse, B.; Beachel, L.; Appelbaum, P.C. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 2009, 53, 4217–4224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Ng, E.Y.; Trucksis, M.; Hooper, D.C. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 1996, 40, 1881–1888. [Google Scholar] [CrossRef] [Green Version]
  26. Ferrero, L.; Cameron, B.; Crouzet, J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 1995, 39, 1554–1558. [Google Scholar] [CrossRef] [Green Version]
  27. Saitou, N.; Nei, M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4, 406–425. [Google Scholar] [CrossRef]
  28. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol. 2018, 35, 1547–1549. [Google Scholar] [CrossRef]
  29. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.; M07; CLSI: Wayne, PA, USA, 2018. [Google Scholar]
  30. Clinical and Laboratory Standards Institute. Reference Methods for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, 3rd ed.; M38; CLSI: Wayne, PA, USA, 2017. [Google Scholar]
  31. Farrell, D.J.; Robbins, M.; Rhys-Williams, W.; Love, W.G. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob. Agents Chemother. 2011, 55, 1177–1181. [Google Scholar] [CrossRef] [Green Version]
Marinedrugs 18 00522 g001 550
Figure 1. A neighbor-joining phylogenetic tree of strain MBTI36 based on 16S rDNA sequence. The phylogenetic tree was constructed using MEGA-X software (Molecular Evolutionary Genetics Analysis, version 10) and bootstrap was replicated a thousand times. The Kimura two-parameter model considering transversional and transitional substitution rates was used to measuring distance. Bar indicates 10 nucleotide substitutions per 1000 sites. T: type strain.
Figure 1. A neighbor-joining phylogenetic tree of strain MBTI36 based on 16S rDNA sequence. The phylogenetic tree was constructed using MEGA-X software (Molecular Evolutionary Genetics Analysis, version 10) and bootstrap was replicated a thousand times. The Kimura two-parameter model considering transversional and transitional substitution rates was used to measuring distance. Bar indicates 10 nucleotide substitutions per 1000 sites. T: type strain.
Marinedrugs 18 00522 g001
Marinedrugs 18 00522 g002 550
Figure 2. The structures of compounds 1–4.
Figure 2. The structures of compounds 1–4.
Marinedrugs 18 00522 g002
Marinedrugs 18 00522 g003 550
Figure 3. Key correlations of COSY (bold) and HMBC (arrows) experiments for compound 1.
Figure 3. Key correlations of COSY (bold) and HMBC (arrows) experiments for compound 1.
Marinedrugs 18 00522 g003
Marinedrugs 18 00522 g004 550
Figure 4. Resistance acquisition during 21 serial passaging (21 days) in the presence of sub-MIC (0.5 × the MIC determined from the previous passage) levels of ciprofloxacin, chromomycin A9 (1), Ap (2), A2 (3), and A3 (4) for S. aureus ATCC43300. The y axis is the highest concentration the cells grew to during passaging. For ciprofloxacin, 128 × MIC was the highest concentration tested. The figures are representative of three independent experiments.
Figure 4. Resistance acquisition during 21 serial passaging (21 days) in the presence of sub-MIC (0.5 × the MIC determined from the previous passage) levels of ciprofloxacin, chromomycin A9 (1), Ap (2), A2 (3), and A3 (4) for S. aureus ATCC43300. The y axis is the highest concentration the cells grew to during passaging. For ciprofloxacin, 128 × MIC was the highest concentration tested. The figures are representative of three independent experiments.
Marinedrugs 18 00522 g004
Table
Table 1. 13C and 1H NMR assignments for compound 1 in CDCl3 a.
Table 1. 13C and 1H NMR assignments for compound 1 in CDCl3 a.
PositionδC, TypeδH (J in Hz)PositionδC, TypeδH (J in Hz)
1202.3, C 4-O-methyl-d-oliose (Sugar B)
276.1, CH4.72, d (11.4)B195.4, CH5.11, br s
344.0, CH2.60, mB233.7, CH21.76, m; 1.73, m
427.1, CH23.10, mB366.0, CH3.96, m
2.67, dd (16.6, 3.5)B481.7, CH3.22, d (2.8)
5101.0, CH6.64, sB566.9, CH3.87, q (6.6)
6159.9, C B617.4, CH1.28, d (6.3)
7111.9, C B4-OCH362.6, CH33.60, s
8156.3, C d-olivose (Sugar C)
9165.5, C C1100.5, CH5.10, dd (9.7, 1.3)
10117.2, CH6.75, sC237.7, CH22.48, m; 1.70, m
4a134.8, C C382.5, CH3.61, m
8a108.3, C C475.3, CH3.12, m
9a108.3, C C572.3, CH3.38, m
10a138.6, C C618.2, CH31.35, d (5.6)
7-CH38.4, CH38.40, sd-olivose (Sugar D)
8-OH 9.81, sD199.9, CH4.60, dd (9.6, 1.7)
1′82.0, CH4.70, d (1.5)D237.3, CH22.28, m; 1.70, m
2′211.3, C D380.9, CH3.50, m
3′78.3, C4.22, br sD475.4, CH3.12, m
4′68.1, C4.36, mD572.5, CH3.30, m
5′20.8, CH31.37, d (5.6)D618.0, CH31.24, d (6.1)
1′-OCH359.9, CH33.52, sl-chromose (Sugar E)
4-O-propioyl-d-oliose (Sugar A)E197.3, CH5.02, dd (3.6, 1.8)
A197.6, C5.21, dd (9.7, 2.0)E243.9, CH22.04, m; 2.00, m
A233.2, CH22.19, m; 2.05, mE370.8, C
A370.2, CH3.98, mE479.9, CH4.61, d (9.3)
A467.2, CH5.18, d (2.9)E567.2, CH3.98, m
A570.03.82, q (6.5)E618.0, CH31.38, d (5.4)
A617.0, C1.28, d (6.3)E3-CH323.2, CH31.35, s
COCH2CH3174.6, C COCH3171.7, C
COCH2CH327.8, CH22.46, q (7.5)COCH321.1, CH32.14, s
COCH2CH39.7, CH31.19, t (7.5)
a 13C and 1H NMR data were obtained at 100 and 400 MHz, respectively.
Table
Table 2. Results of antimicrobial activity test.
Table 2. Results of antimicrobial activity test.
CompoundMIC (μg/mL)
Gram (+) BacteriaGram (−) BacteriaFungi
ABCDEFGHIJ
10.030.50.130.5>128>128>128>128>128>128
20.130.50.131>128>128>128>128>128>128
30.060.50.060.5>128>128>128>128>128>128
40.130.50.130.5>128>128>128>128>128>128
Ampicillin0.060.50.250.2512832
Tetracycline0.060.130.250.250.50.5
Amphotericin B 0.5111
A: Staphylococcus aureus ATCC25923, B: Enterococcus faecium ATCC19434, C: Enterococcus faecalis ATCC19433, D: Salmonella enterica ATCC14028, E: Klebsiella pneumoniae ATCC10031, F: Escherichia coli ATCC25922, G: Candida albicans ATCC10231, H: Aspergillus fumigatus HIC6094, I: Trichophyton rubrum NBRC9185, J: Trichophyton mentagrophytes IFM40996.
Table
Table 3. Antibacterial activities of compounds 1–4 against MSSA and MRSA strains.
Table 3. Antibacterial activities of compounds 1–4 against MSSA and MRSA strains.
MicroorganismMIC (μg/mL)
DapVanPlaLinCip1234
CCARM0027 a80.5420.250.130.130.060.13
CCARM0204 a20.25410.250.060.060.030.06
CCARM0205 a10.13210.250.060.130.060.06
CCARM3640 a80.25420.250.130.250.060.13
CCARM3089 b>32182>320.130.250.130.13
CCARM3090 b>32181>320.130.250.130.13
CCARM3634 b>320.582>320.130.130.060.13
CCARM3635 b>32182>320.130.060.060.13
ATCC43300 b>321420.250.130.130.060.13
ATCC700787 b>322820.130.130.250.250.13
ATCC700788 b>32282160.130.250.130.13
a Methicillin-sensitive Staphylococcus aureus (MSSA). b Methicillin-resistant Staphylococcus aureus (MRSA). Dap: daptomycin, Van: vancomycin, Pla: platensimycin, Lin: Linezolid, Cip: ciprofloxacin.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Cho, E.; Kwon, O.-S.; Chung, B.; Lee, J.; Sun, J.; Shin, J.; Oh, K.-B. Antibacterial Activity of Chromomycins from a Marine-Derived Streptomyces microflavus. Mar. Drugs 2020, 18, 522. https://doi.org/10.3390/md18100522

AMA Style

Cho E, Kwon O-S, Chung B, Lee J, Sun J, Shin J, Oh K-B. Antibacterial Activity of Chromomycins from a Marine-Derived Streptomyces microflavus. Marine Drugs. 2020; 18(10):522. https://doi.org/10.3390/md18100522

Chicago/Turabian Style

Cho, Eunji, Oh-Seok Kwon, Beomkoo Chung, Jayho Lee, Jeongyoon Sun, Jongheon Shin, and Ki-Bong Oh. 2020. "Antibacterial Activity of Chromomycins from a Marine-Derived Streptomyces microflavus" Marine Drugs 18, no. 10: 522. https://doi.org/10.3390/md18100522

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop